Physician profile
Salvatore Focella
NPI 1013901511
$4,683.68
in general payments reported to CMS, 2019-2025
19 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $292 · 2021: $421 · 2022: $607 · 2023: $888 · 2024: $738 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $697.30 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $654.20 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $602.24 | 2021-2023 | Ingrezza |
| Gilead Sciences, INC. | $397.48 | 2023-2025 | Biktarvy, Epclusa |
| Abbvie INC. | $358.48 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $356.32 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $352.55 | 2020-2024 | Uzedy |
| Janssen Pharmaceuticals, INC | $252.86 | 2024-2025 | Invega Sustenna |
| Astrazeneca Pharmaceuticals LP | $194.77 | 2022-2025 | Lokelma, Farxiga |
| Amarin Pharma, INC. | $193.22 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $174.29 | 2019-2021 | |
| Allergan, INC. | $124.82 | 2020 | |
| Axsome Therapeutics, INC. | $121.29 | 2025 | Auvelity |
| Shionogi INC | $110.16 | 2025 | Fetroja |
| Kowa Pharmaceuticals America, INC. | $25.81 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $23.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.84 | 2019 | |
| Pfizer INC. | $14.86 | 2019 | |
| Dynavax Technologies Corporation | $13.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvatore Focella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.